CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04+0.00 (0.00%)
Close on Nov 13, 2026Market cap $444.52MP/E –Yield –
CytomX Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
CytomX Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -609.0%. For fiscal 2025 it was -22.8%, against 23.1% the year before. The highest annual figure on record is 23.1% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -22.8% | −45.9 |
| FY2024 | Dec 31, 2024 | 23.1% | +23.6 |
| FY2023 | Dec 31, 2023 | -0.6% | +186.3 |
| FY2022 | Dec 31, 2022 | -186.8% | +123.7 |
| FY2021 | Dec 31, 2021 | -310.5% | −215.8 |
| FY2020 | Dec 31, 2020 | -94.7% | +399.0 |
| FY2019 | Dec 31, 2019 | -493.7% | −351.5 |
| FY2018 | Dec 31, 2018 | -142.2% | −82.0 |
| FY2017 | Dec 31, 2017 | -60.2% | +331.4 |
| FY2016 | Dec 31, 2016 | -391.5% | +67.1 |
| FY2015 | Dec 31, 2015 | -458.7% | +138.3 |
| FY2014 | Dec 31, 2014 | -597.0% | +1108.3 |
| FY2013 | Dec 31, 2013 | -1705.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1184.7% | −946.1 |
| Q2 FY2026 | Jun 30, 2026 | -1457.4% | −1456.6 |
| Q1 FY2026 | Mar 31, 2026 | -177.9% | −224.1 |
| Q4 FY2025 | Dec 31, 2025 | -3998.5% | −4048.0 |
| Q3 FY2025 | Sep 30, 2025 | -238.6% | −255.8 |
| Q2 FY2025 | Jun 30, 2025 | -0.8% | +25.2 |
| Q1 FY2025 | Mar 31, 2025 | 46.2% | +12.9 |
| Q4 FY2024 | Dec 31, 2024 | 49.6% | +46.4 |
| Q3 FY2024 | Sep 30, 2024 | 17.2% | +5.8 |
| Q2 FY2024 | Jun 30, 2024 | -26.0% | −21.6 |
| Q1 FY2024 | Mar 31, 2024 | 33.3% | +47.4 |
| Q4 FY2023 | Dec 31, 2023 | 3.1% | +46.8 |
| Q3 FY2023 | Sep 30, 2023 | 11.3% | +272.1 |
| Q2 FY2023 | Jun 30, 2023 | -4.4% | +225.1 |
| Q1 FY2023 | Mar 31, 2023 | -14.1% | +339.7 |
| Q4 FY2022 | Dec 31, 2022 | -43.6% | +269.2 |
| Q3 FY2022 | Sep 30, 2022 | -260.7% | +76.4 |
| Q2 FY2022 | Jun 30, 2022 | -229.5% | +74.5 |
| Q1 FY2022 | Mar 31, 2022 | -353.8% | −69.2 |
| Q4 FY2021 | Dec 31, 2021 | -312.8% | +26.2 |
| Q3 FY2021 | Sep 30, 2021 | -337.2% | −1.9 |
| Q2 FY2021 | Jun 30, 2021 | -304.0% | +58.0 |
| Q1 FY2021 | Mar 31, 2021 | -284.6% | −304.9 |
| Q4 FY2020 | Dec 31, 2020 | -339.0% | +89.2 |
| Q3 FY2020 | Sep 30, 2020 | -335.3% | −114.0 |
| Q2 FY2020 | Jun 30, 2020 | -362.0% | −40.7 |
| Q1 FY2020 | Mar 31, 2020 | 20.3% | +68.2 |
| Q4 FY2019 | Dec 31, 2019 | -428.3% | −147.3 |
| Q3 FY2019 | Sep 30, 2019 | -221.2% | −33.9 |
| Q2 FY2019 | Jun 30, 2019 | -321.3% | −258.3 |
| Q1 FY2019 | Mar 31, 2019 | -47.9% | +61.3 |
| Q4 FY2018 | Dec 31, 2018 | -281.0% | −283.3 |
| Q3 FY2018 | Sep 30, 2018 | -187.3% | −144.9 |
| Q2 FY2018 | Jun 30, 2018 | -63.0% | +225.1 |
| Q1 FY2018 | Mar 31, 2018 | -109.2% | −38.4 |
| Q4 FY2017 | Dec 31, 2017 | 2.3% | +226.0 |
| Q3 FY2017 | Sep 30, 2017 | -42.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -288.1% | – |
| Q1 FY2017 | Mar 31, 2017 | -70.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -223.7% | – |
See a number that looks wrong?